In vitro inhibition of aggregation of human erythrocytes by synthetic fibrinolytic compounds.
It has been shown that a variety of synthetic organic anions which induce fibrinolytic activity in human plasma in vitro and which in addition inhibit collagen-induced aggregation of human platelets, also exert to various degrees an inhibition of dextran, fibrinogen and gelatin induced aggregation of human erythrocytes and of the pathologically accelerated erythrocyte sedimentation rate.  Since increased erythrocyte aggregation is contributing to thrombogenesis, ability to prevent erythrocyte aggregation is a desirable feature for synthetic antithrombotic compounds.  They should exert three actions: induce fibrinolytic activity, prevent platelet aggregation, and inhibit erythrocyte aggregation.  This communication refers to prototypes of such compounds.
D001799:Blood Sedimentation; D002449:Cell Aggregation / Q000187:drug effects*; D003094:Collagen / Q000494:pharmacology; D003864:Depression, Chemical; D003911:Dextrans / Q000494:pharmacology; D004912:Erythrocytes / Q000187:drug effects*; D005340:Fibrinogen / Q000494:pharmacology; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D005780:Gelatin / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D010974:Platelet Aggregation / Q000187:drug effects
D003911:Dextrans; D005343:Fibrinolytic Agents; D005780:Gelatin; D005340:Fibrinogen; D003094:Collagen